Peplin is a development-stage company that specializes in medical dermatology products. Their lead product candidate, PEP005, is a patient-applied topical gel used to treat actinic keratosis. They also offer a physician-applied topical gel for the treatment of superficial basal cell carcinoma. Both products use a small molecule extracted from Euphorbia peplus. Peplin was acquired by LEO Pharma A/S and now offers research and development consulting services for biotech and pharma organizations globally, specializing in clinical development.